U.S. Preventive Services 

Task Force banner
U.S. Preventive Services Task Force

You Are Here: U.S. Preventive Services Task Force > Topic Index > Hormone Replacement Therapy

Hormone Replacement Therapy for the Prevention of Chronic Conditions in Postmenopausal Women

This topic is in the process of being updated. Please go to the Update in Progress section to see the latest documents available.


This topic page summarizes the U.S. Preventive Services Task Force (USPSTF) recommendations on hormone replacement therapy.



Current Recommendation

Release Date: May 2005

  • The USPSTF recommends against the routine use of combined estrogen and progestin for the prevention of chronic conditions in postmenopausal women.
    Grade: D Recommendation.
  • The USPSTF recommends against the routine use of unopposed estrogen for the prevention of chronic conditions in postmenopausal women who have had a hysterectomy.
    Grade: D Recommendation.

Supporting Documents

Recommendation Statement (PDF File, 102 KB; PDF Help)
Summary of the Evidence, 2002 (PDF File, 138 KB; PDF Help)
Systematic Evidence Reviews, 2002
   HRT and Breast Cancer (PDF Files Download)
   HRT and Cardiovascular Disease (PDF Files Download)
   HRT and Cognition (PDF Files Download)
   HRT and Osteoporosis (PDF Files Download)
   HRT and Venous Thromboembolism (PDF Files Download)

Update in Progress

In an effort to make the USPSTF recommendations clearer and its processes more transparent, the Task Force is sharing drafts of many of its documents for public comment, including draft Research Plans and draft Recommendation Statements. As a result, the final Recommendation Statement is not yet available.


Supporting Documents

Evidence Report

The research team at the Evidence-based Practice Center independently gathers and reviews the available published evidence to address the questions posed by the USPSTF. The resulting draft Evidence Report is critiqued by national subject matter experts before being finalized.

Evidence Report Related Items
Evidence Report (PDF File, 164 KB; PDF Help) Evidence Synthesis (PDF File, 1 MB; PDF Help)

Recommendation Statement

The USPSTF reviews the Evidence Report, evaluates the benefits and harms of the clinical preventive service, and discusses and develops one or more preliminary specific recommendations. The resulting draft Recommendation Statement is posted on this Web site for public comment before being finalized.

Recommendation Statement Related Items
Draft Recommendation Statement for Public Comment*
(May 29–June 26, 2012)
Consumer Fact Sheet (PDF File, 442 KB; PDF Help)

* Note: Draft Recommendation Statements are by their nature not final, and should not be interpreted as to represent official USPSTF recommendations for practice. Draft Recommendation Statements are provided by the USPSTF for informational purposes only.

 

Current as of June 2012


Internet Citation:

Hormone Replacement Therapy for the Prevention of Chronic Conditions in Postmenopausal Women, Topic Page. May 2012. U.S. Preventive Services Task Force. http://www.uspreventiveservicestaskforce.org/uspstf/uspspmho.htm


 


USPSTF Program Office   540 Gaither Road, Rockville, MD 20850